EXEL

Exelixis, Inc. NMS · EXEL

$55.53 -0.39 (-0.70%)

Neutral · +0.44σ

+ Compare Open in Sniper

Mkt cap $14.0B

P/E 18.4

Day $55.50 – $56.69

52wk $39.71 – $57.57

Avg vol 2.7M

Beta 0.42

Div yld —

Next earnings 2026-08-04

Quick read

Plain English

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

EXEL last traded at $55.53, down 0.7% on the day; that's in the upper part of its 52-week range ($39.71–$57.57). Right now it's trading close to its recent average, with no strong stretch in either direction.

The next scheduled earnings report (2026-08-04) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

KC1 upper, +0.38 ATR from EMA21 — no notable pattern

Long —

score 16 · tech 16 / 80 · support 0 / 20

above KC1 lower, +0.38 ATR from EMA21 · no notable pattern

· Aligned with strong uptrend (strong tailwind)

How this grade was earned

total 16 pts

Cycle position 6

Market fit 10

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

score 20 · tech 20 / 80 · support 0 / 20

KC1 upper, +0.38 ATR from EMA21 · no notable pattern

· KC1 upper stretch — light pop
· RSI hook from overbought (57)
· Counter-trend short in strong uptrend

How this grade was earned

total 20 pts

Cycle position 14

Momentum 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $61.28 (fair range $28–$61); today's price leaves a +7% cushion below that estimate. The model's verdict is “Fair” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.

Intrinsic (DCF)

$61.28

Fair-value range

$27.69 – $61.28

Margin of safety

+7%

Verdict

Fair

Accounting quality Adequate

✓ More cash than debt
✓ Quick ratio 2.62 (antifragile)
✓ Current ratio 3.56 (antifragile)
✓ Debt/equity 0.32 (antifragile)

⚠ Negative retained earnings

Price implies ~9% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

EXEL is a $14.0 billion company, priced at 18× last year's earnings, and it moves more calmly than the market (beta 0.4); the stock is trading near the top of its 52-week range.

Mkt cap $14.0B

P/E ttm 18.4

Fwd P/E 14.0

Beta 0.42

Day range $55.50 – $56.69

52w range $39.71 – $57.57

Avg vol 2.7M

RSI(2) 26.2

ROE 41.0%

Net mgn 35.1%

FCF mgn 26.5%

Debt/Eq 0.09

Div yld —

Sector Healthcare

Industry Biotechnology

Next earn 2026-08-04

52-week range · today's price

$39.71$57.57

More on EXEL

Options idea

See more →

CALL $55 2026-08-21

$3.50

PUT $55 2026-08-21

$2.45

Earnings

See more →

Last reported: 2026-05-05
EPS (act / est): 0.87 / 0.76
Surprise: +14.0%
Next report: 2026-08-04

About

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metasta…